Business

Eli Lilly Pledges $5 Billion for New Virginia Facility to Strengthen Domestic Pharmaceutical Production

The facility—planned for the West Creek Business Park—will focus on producing active pharmaceutical ingredients (APIs) and drug products tied to monoclonal antibodies, antibody-drug conjugates, cancer therapy, autoimmune conditions, and other advanced biologics.

• By Newsdesk
• New Delhi
• Sep 17, 2025

Business

Eli Lilly & Co. has announced plans to invest $5 billion to build a state-of-the-art manufacturing plant in Goochland County, Virginia, aiming to reinforce U.S. drug supply chains and produce medicines for critical disease areas.

The facility—planned for the West Creek Business Park—will focus on producing active pharmaceutical ingredients (APIs) and drug products tied to monoclonal antibodies, antibody-drug conjugates, cancer therapy, autoimmune conditions, and other advanced biologics. Construction is expected to generate around 1,800 jobs, while once fully operational, the plant will employ approximately 650 skilled workers including engineers, scientists, and lab technicians.

Strategic Context & Broader Investment Plans

This Virginia facility is the first of four new U.S. plants Lilly has committed to under a larger domestic manufacturing expansion. The broader plan, announced earlier in 2025, allocates about $27 billion toward these four new sites.

Eli Lilly’s leadership has emphasized that the investment responds to evolving global manufacturing risks, such as supply chain disruptions and trade uncertainties. By investing domestically, the company aims to improve resilience in sourcing and production of essential raw materials and innovative therapeutics.

Local & Economic Impact

Virginia’s Governor Glenn Youngkin described the decision as a “significant commitment” that boosts both the state’s economy and its standing in biopharma innovation. The project is seen as a mark of Virginia’s growing appeal for pharmaceutical manufacturing, thanks to its skilled workforce, favorable location, and growing life sciences infrastructure.

Officials also expect this facility to have ripple effects: job creation beyond those directly employed, spin-off benefits for suppliers and contractors, and long-term economic stimulus in the surrounding communities.